A new nanocarrier was developed to address the debilitating side effects associated with cancer treatment, specifically for delivering Sorafenib (SF). This nanocarrier utilises biodegradable polymers, which present a promising approach to anti-cancer therapy by enabling controlled drug release and reduced toxicity. The design of the nanocarrier includes Fe3O4 nanoparticles, Sodium alginate, Lignosulphonic acid, Polyethylene glycol, SF drug, and a MgAl layered double hydroxide coating. The nanocarrier was extensively characterised using various techniques, including FT-IR, TGA, and FESEM. Notably, the IONP nanocarrier demonstrated remarkable superiority in the controlled release of SF compared to other variations. The chemical interactions among the components of the nanocarrier significantly contributed to its enhanced stability, as evidenced by thermogravimetric analysis. Furthermore, XRD analysis confirmed the crystalline nature of the final samples. The FESEM images provided visual confirmation of the morphology of the nanocarrier combinations. Additionally, kinetic models verified the sustained release of SF from the composite alginate matrix. These findings collectively highlight the potential of this nanocarrier system as an effective approach for delivering SF drug in cancer treatment while minimising side effects.